The 3 studies summarised were CA184-008, CA184-022, CA184-007.
The results clearly showed that:
- 12 month survival rates were >47%
- 18 month survival rates were >34%
- 24 month survival rates were >30%
"For previously treated patients, 24 month survival rates ranged from 24% to 33%.
Long term survivors included patients with progressive disease according to WHO criteria.
These results are promising but caution must be extended because a significant number of patients were lost to follow-up, which may reduce the reliability of the results. Ongoing biomarker studies are looking at predicting which patients are most likely to benefit from ipilumumab therapy.
What did we learn from these trials? Well, there is an urgent need to define optimal endpoints for melanoma clinical trials in terms of response rate, PFS, OS and survival at 12 months. It is interesting that over the past 10 years the majority of abstracts have hyped the results in this disease as 'promising' or 'clinically active' regimens and yet very little in the way of new therapies have actually been approved by the FDA. Based on these data, I suspect it will still be a little while before we see some solid phase III data in malignant melanoma."